Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluating subcutaneous emicizumab in infants from birth to 12 months with Hemophilia A, covering efficacy, safety, pharmacokinetics, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Hemlibra (emicizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Severe Hemophilia A | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-14